代謝組學市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、適應症、應用、地區和競爭細分，2019-2029F

2023 年全球代謝組學市場估值為22.2 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為8.23%。個關鍵因素推動。分析技術的進步，特別是質譜和核磁共振（NMR）波譜，顯著增強了代謝組學研究小分子代謝物的能力。這些技術進步使研究人員能夠以更高的準確性和靈敏度識別和量化生物樣本中的各種代謝物。代謝組學在製藥、生物技術、環境科學和個人化醫療等各領域的應用不斷增加，正在擴大市場。代謝組學擴大用於生物標記發現、藥物開發和了解疾病機制，這增加了其需求。研發活動投資的增加，加上政府和私部門不斷增加的資助舉措，進一步推動了市場的成長。這些投資旨在開發創新的代謝組學解決方案，並擴大代謝組學在醫療保健和其他行業的應用領域。

市場概況
預測期	2025-2029
2023 年市場規模	22.2億美元
2029 年市場規模	35.8億美元
2024-2029 年複合年成長率	8.23%
成長最快的細分市場	癌症
最大的市場	北美洲

主要市場促進因素

技術進步

生物醫學研究中的應用

對個人化醫療的需求不斷成長

在農業和食品科學中不斷成長的應用

主要市場挑戰

標準化和品質控制

數據處理與分析

主要市場趨勢

與組學方法的整合

增加藥物發現和開發的採用

細分市場洞察

產品洞察

適應症見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球代謝組學市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（代謝組學儀器、代謝組學生物資訊學工具及服務）
  • 按適應症（癌症、心血管疾病、神經系統疾病、先天性代謝缺陷等）
  • 按應用（生物標記和藥物發現、毒理學、營養基因組學、個人化醫療等）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖

第 6 章：北美代謝組學市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按指示
  • 按申請
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲代謝組學市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按指示
  • 按申請
  • 按國家/地區
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太代謝組學市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按指示
  • 按申請
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲代謝組學市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按指示
  • 按申請
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲代謝組學市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按指示
  • 按申請
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最近的發展

第 13 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第14章：競爭格局

• Metabolon, Inc.
• Agilent Technologies, Inc.
• Bruker Corporation
• Human Metabolome Technologies America, Inc.
• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• Danaher Corporation
• Waters Corporation
• Metware Biotechnology Inc.
• Afekta Technologies Ltd.

第 15 章：策略建議

第16章調查會社について,免責事項

Global Metabolomics Market was valued at USD 2.22 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.23% through 2029. The Global Metabolomics Market is driven by several key factors contributing to its growth. Advancements in analytical technologies, particularly mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, have significantly enhanced the capabilities of metabolomics in studying small molecule metabolites. These technological advancements have enabled researchers to identify and quantify a wide range of metabolites in biological samples with greater accuracy and sensitivity. Increasing applications of metabolomics in various fields such as pharmaceuticals, biotechnology, environmental science, and personalized medicine are expanding the market. Metabolomics is increasingly used for biomarker discovery, drug development, and understanding disease mechanisms, which has heightened its demand. Rising investments in research and development activities, coupled with growing funding initiatives from government and private sectors, are further fueling market growth. These investments are aimed at developing innovative metabolomic solutions and expanding the application areas of metabolomics in healthcare and other industries.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 2.22 Billion
Market Size 2029	USD 3.58 Billion
CAGR 2024-2029	8.23%
Fastest Growing Segment	Cancer
Largest Market	North America

Key Market Drivers

Technological Advancements

Advances in analytical technologies such as mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and chromatography have heralded a new era in metabolomics research and applications. These technologies have significantly evolved, enabling researchers to detect, identify, and quantify metabolites in biological samples with unprecedented sensitivity and accuracy. Mass spectrometry, for instance, allows for the precise measurement of molecular masses and fragmentation patterns of metabolites, facilitating their identification even in complex mixtures. It has become indispensable in metabolomics due to its ability to provide detailed structural information about metabolites.

Nuclear magnetic resonance (NMR) spectroscopy, on the other hand, offers non-destructive analysis and is particularly valuable for the identification and quantification of metabolites in intact biological samples. Its ability to detect isotopic labeling and subtle structural changes in molecules makes it a powerful tool in metabolomics studies. Chromatography techniques, including liquid chromatography (LC) and gas chromatography (GC), are essential for separating metabolites based on their chemical properties before analysis. Coupled with mass spectrometry or NMR spectroscopy, chromatography enhances the resolution and sensitivity of metabolomic analyses.

In addition to these advancements in hardware, improvements in data analysis software have played a crucial role in metabolomics. Advanced algorithms and computational tools allow for the processing, alignment, and interpretation of large-scale metabolomic data sets. This capability is essential for extracting meaningful biological insights from complex data. Automation has streamlined workflows in metabolomics laboratories, increasing throughput and reducing human error. Automated sample preparation, data acquisition, and analysis pipelines have improved the reproducibility and reliability of metabolomic experiments, making metabolomics more accessible and practical across various industries.

Applications in Biomedical Research

Metabolomics has emerged as a pivotal field within biomedical research, offering profound insights into the intricate metabolic pathways and alterations that underpin various diseases. By profiling and quantifying metabolites present in biological samples, metabolomics enables researchers to delve deep into the biochemical fingerprints of diseases like cancer, diabetes, and cardiovascular disorders. One of the primary applications of metabolomics is biomarker discovery. By identifying specific metabolite signatures associated with disease states, metabolomics facilitates the development of biomarkers that can aid in early diagnosis, prognosis, and monitoring of disease progression. These biomarkers hold immense potential for improving clinical outcomes by enabling timely interventions and personalized treatment plans tailored to individual patient profiles. BME researcher's and collaborators are embarking on a groundbreaking initiative to construct a comprehensive chemical atlas detailing all immune cells within the human body. This ambitious project aims to create a 3D micromap that will aid clinicians in navigating the intricate role of the immune system across various diseases, ultimately enhancing precision therapies for patients. Their endeavor begins at the cellular level, utilizing a new integrative technique designed to profile human tissue with unprecedented detail. Known as the Single Cell Spatially resolved Metabolic (scSpaMet) framework, this innovative approach enables researchers to capture the spatial distribution, structure, dynamics, and functional characteristics of molecules within a three-dimensional context. Published in Nature Communications on December 13, the scSpaMet framework builds upon a previous advancement introduced by Coskun's team in 2021. Their earlier work, detailed in the article "3D Spatially resolved Metabolomic profiling Framework" published in Science Advances, focused on profiling metabolite and protein activity across human tissue samples. This foundation laid the groundwork for their current efforts to expand understanding through enhanced spatial resolution and metabolic insight, paving the way for significant advancements in biomedical research and clinical practice.

Metabolomics contributes significantly to understanding disease mechanisms at a molecular level. By uncovering metabolic dysregulations linked to disease onset and progression, researchers gain valuable insights into the underlying biochemical pathways involved. This knowledge not only enhances our fundamental understanding of diseases but also informs the development of targeted therapies aimed at correcting metabolic imbalances. In drug development, metabolomics plays a crucial role in evaluating drug efficacy, safety, and toxicity. By assessing how drugs influence metabolic pathways and alter metabolite profiles, researchers can optimize drug candidates and predict potential adverse effects early in the development process. This approach accelerates the discovery of novel therapeutics and supports precision medicine initiatives by identifying patient-specific responses to treatment.

Rising Demand for Personalized Medicine

The transition towards personalized medicine has catalyzed a growing interest in metabolomics, driven by its ability to uncover individual variations in metabolic profiles. This capability is crucial in tailoring treatment strategies and optimizing therapeutic outcomes based on a patient's unique biochemical makeup. Metabolomics plays a pivotal role in identifying biomarkers that indicate how individuals metabolize drugs and respond to treatments. By profiling metabolites present in biological samples, metabolomics provides valuable insights into metabolic pathways and their alterations in response to therapeutic interventions. This information is essential for predicting drug efficacy and potential toxicity, guiding clinicians in selecting the most suitable medications and dosages for individual patients. According to an article titled "Tackling new psychoactive substances through metabolomics: UHPLC-HRMS study on natural and synthetic opioids in male and female murine models", the research endeavors to establish an indirect screening approach for monitoring NPS, particularly new synthetic opioids (NSOs). This strategy focuses on assessing changes in endogenous urinary metabolite levels following the systemic response to their consumption. The study employed in-vivo mouse models where 16 animals of both sexes received a single dose of either morphine or fentanyl. Urine samples were collected before and after drug administration at multiple time intervals. Subsequently, these samples underwent analysis using an untargeted metabolomics LC-HRMS workflow. The experimental framework aims to elucidate metabolic alterations induced by NSOs, leveraging sophisticated analytical techniques to identify potential biomarkers associated with their ingestion. This approach not only seeks to enhance understanding of NPS metabolism but also to develop effective strategies for their detection and surveillance amidst the complex challenges posed by evolving drug compositions in illicit markets.

Metabolomic profiling contributes to monitoring therapeutic responses over time. By tracking changes in metabolic profiles before and after treatment, healthcare providers can assess treatment effectiveness, adjust therapies as necessary, and minimize adverse effects. This proactive approach to healthcare management improves patient outcomes by ensuring that treatments are personalized and optimized based on real-time metabolic data. In drug development, metabolomics offers significant advantages by identifying metabolic biomarkers associated with drug targets and disease pathways. This facilitates the discovery of new therapeutic agents and supports precision medicine initiatives aimed at developing tailored treatments for specific patient populations.

Growing Applications in Agriculture and Food Sciences

Metabolomics has emerged as a valuable tool in agricultural research, offering insights into the metabolic processes of plants and crops that are crucial for enhancing yield, quality, and resilience against environmental stresses. By analyzing the complete set of small molecules or metabolites within plants, metabolomics enables researchers to understand biochemical pathways involved in growth, development, and responses to biotic and abiotic stresses. This knowledge is instrumental in breeding programs aimed at developing new crop varieties with improved traits such as disease resistance, nutrient uptake efficiency, and tolerance to drought or extreme temperatures.

In food sciences, metabolomics plays a pivotal role in ensuring food safety, authenticity, and nutritional quality. It enables comprehensive profiling of food metabolites, contaminants, and bioactive compounds, offering a detailed assessment of food composition and quality. Metabolomic approaches are applied throughout the food production chain-from farm to table-to monitor changes in metabolite composition during cultivation, harvesting, processing, storage, and distribution. This capability supports efforts to optimize food processing methods, reduce food waste, and maintain nutritional integrity.

Key Market Challenges

Standardization and Quality Control

Achieving standardized protocols and implementing quality control measures across laboratories and platforms is a critical hurdle in the field of metabolomics. The variability in sample handling, analytical techniques, and data analysis poses challenges to the reproducibility and comparability of metabolomic data.

One of the primary challenges is the lack of uniformity in sample collection, preparation, and storage methods among different research groups and facilities. Variations in these steps can introduce biases and artifacts, impacting the accuracy and reliability of metabolomic results. Standardization efforts aim to establish consistent protocols for sample handling, including the use of standardized collection tubes, storage conditions (temperature, duration), and procedures for extraction and derivatization.

The diversity in analytical techniques used for metabolite detection-such as mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and chromatography-adds complexity. Each method has its strengths and limitations, and differences in instrumentation settings, data acquisition protocols, and data processing algorithms can lead to variations in results. Harmonizing these analytical approaches through method validation and inter-laboratory comparisons is essential to ensure data reproducibility and comparability. Data analysis also presents challenges, as metabolomics datasets are large, complex, and multidimensional. Standardizing data processing workflows, including normalization, feature selection, statistical analysis, and bioinformatics tools, is crucial. Variability in these computational steps can lead to divergent interpretations and hinder the integration of metabolomic data with other omics datasets.

Data Processing and Analysis

Metabolomics, as a rapidly advancing field, generates vast amounts of complex data that pose significant challenges in data processing, analysis, and interpretation. These challenges stem from the multidimensional nature of metabolomics datasets and the need for sophisticated computational tools and bioinformatics expertise. One of the primary challenges is data normalization, which aims to minimize systematic variations introduced during sample preparation, data acquisition, and instrument settings. Variability in experimental conditions and analytical platforms can lead to differences in metabolite abundance, making it essential to develop robust normalization strategies. Normalization methods must account for factors such as sample volume, matrix effects, and instrumental drift to ensure accurate comparisons across samples and studies.

Statistical analysis is another critical aspect of metabolomics data interpretation. Due to the high dimensionality of metabolomic datasets (often thousands of metabolite features), selecting appropriate statistical tests and correction methods for multiple comparisons is crucial. Statistical approaches such as univariate and multivariate analysis, regression modeling, and machine learning algorithms are employed to identify significant biomarkers, classify samples, and uncover metabolic pathways associated with biological phenomena or disease states.

Key Market Trends

Integration with Omics Approaches

Integration of metabolomics with other omics disciplines such as genomics, proteomics, and transcriptomics represents a transformative approach in systems biology research. Each omics discipline provides unique insights into different layers of biological information, and when combined, they offer a comprehensive view of cellular processes, disease mechanisms, and organismal responses. Genomics focuses on the study of an organism's complete set of DNA, providing information about genetic variations, mutations, and their potential implications for phenotype. Transcriptomics examines the complete set of RNA transcripts within a cell or tissue, revealing gene expression patterns and regulatory mechanisms. Proteomics, on the other hand, investigates the entire complement of proteins produced by an organism, offering insights into protein structure, function, and interactions.

By integrating metabolomics with genomics, proteomics, and transcriptomics, researchers can elucidate complex relationships between genes, proteins, and metabolites within biological systems. This integrative approach enables scientists to identify biomarkers of disease, understand metabolic pathways underlying physiological processes, and unravel molecular mechanisms of drug action and toxicity. For instance, in cancer research, integrating metabolomics with genomics and proteomics can help identify metabolic signatures associated with tumor progression and response to therapy. This holistic understanding can guide the development of personalized treatment strategies tailored to individual patients based on their unique molecular profiles.

Increasing Adoption in Drug Discovery and Development

Metabolomics plays a critical role in the drug discovery and development process by providing invaluable insights into the metabolic changes induced by drugs within biological systems. This approach involves the comprehensive analysis of small molecule metabolites present in biofluids, tissues, or cells, offering unique advantages in understanding drug response, toxicity, and efficacy. During the preclinical phase, metabolomics contributes to the identification and validation of biomarkers that indicate how drugs interact with biological pathways. By profiling metabolites in animal models or cell cultures treated with experimental compounds, researchers can discern metabolic signatures associated with drug-induced effects. These biomarkers serve as indicators of pharmacological activity, helping prioritize lead compounds for further development.

In clinical trials, metabolomics enhances pharmacokinetic and pharmacodynamic assessments by elucidating how drugs are absorbed, distributed, metabolized, and excreted in the body. By analyzing metabolite profiles in patient samples, such as blood, urine, or cerebrospinal fluid, metabolomics provides quantitative data on drug metabolism and systemic effects. This information aids in dose optimization, patient stratification based on metabolic phenotypes, and prediction of treatment outcomes. Metabolomic profiling enables early detection of drug-induced toxicity or adverse effects. By monitoring changes in metabolic pathways associated with cellular stress or organ damage, researchers can identify potential safety concerns before they manifest clinically. This proactive approach enhances drug safety assessments and minimizes the risk of adverse reactions in clinical trials and post-marketing surveillance.

Segmental Insights

Product Insights

Based on the product, the dominant segment is Metabolomics Bioinformatics Tools & Services in the global metabolomics market. However, bioinformatics tools and services play a crucial role in metabolomics research and applications for several reasons. Metabolomics generates vast amounts of complex data that require sophisticated computational tools for processing, analysis, and interpretation. Bioinformatics tools help researchers manage this data by normalizing, analyzing, and integrating it with other omics data (genomics, proteomics, etc.). This capability is essential for understanding metabolic pathways, identifying biomarkers, and discovering potential drug targets.

Bioinformatics services provide specialized expertise and support for metabolomics studies. They offer custom data analysis, statistical modeling, pathway analysis, and visualization tools tailored to metabolomics research needs. These services are valuable for academic institutions, pharmaceutical companies, and biotechnology firms engaged in metabolomics-driven research and development. Advancements in bioinformatics have led to the development of user-friendly interfaces and platforms that enhance accessibility for researchers with varying levels of computational expertise. This accessibility fosters collaboration and accelerates scientific discovery in metabolomics.

Indication Insights

Based on the Indication, Cancer dominates the global metabolomics market due to its critical role in biomarker discovery, personalized medicine, and understanding tumor metabolism. Metabolomics enables the identification of metabolic signatures specific to different cancer types and stages, facilitating early detection and precise diagnosis. This capability is crucial for developing non-invasive diagnostic tools and monitoring treatment responses effectively. Metabolomics helps unravel the intricate metabolic pathways within tumors, shedding light on cancer pathogenesis and identifying potential therapeutic targets. In personalized medicine, metabolomics assists in predicting individual responses to cancer therapies, optimizing treatment strategies, and minimizing adverse effects. It also plays a pivotal role in drug development by evaluating drug efficacy and toxicity, thereby advancing precision oncology. Overall, the application of metabolomics in cancer research and clinical practice underscores its significant impact on improving patient outcomes and advancing cancer care globally.

Regional Insights

North America has been a key player in the metabolomics sector for several reasons. The region boasts advanced healthcare infrastructure, comprising leading research institutions, biotechnology companies, and academic centers. This infrastructure facilitates cutting-edge research and development in metabolomics, leveraging state-of-the-art technologies and methodologies.

North America benefits from significant investments in biomedical research, including substantial government funding and private sector support. These investments drive continuous innovation in metabolomics, fostering the development of new biomarkers, diagnostics, and therapeutic strategies. The region's emphasis on personalized medicine and precision healthcare further propels the adoption of metabolomics technologies. Metabolomics plays a crucial role in understanding disease mechanisms, identifying biomarkers, and optimizing treatment approaches tailored to individual patient needs. North America's collaborative ecosystem between academia, industry, and healthcare providers accelerates the translation of metabolomics research into clinical applications. This collaborative environment enhances the validation and commercialization of metabolomics-based products and services.

Key Market Players

Metabolon, Inc.

Agilent Technologies, Inc.

Bruker Corporation

Human Metabolome Technologies America, Inc.

Thermo Fisher Scientific Inc.

Shimadzu Corporation

Danaher Corporation

Waters Corporation

Metware Biotechnology Inc.

Afekta Technologies Ltd.

Report Scope:

In this report, the Global Metabolomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolomics Market, By Product:

Metabolomics Instruments Metabolomics Bioinformatics Tools & Services

Metabolomics Market, By Indication:

Cancer Cardiovascular Disorders Neurological Disorders Inborn Errors of Metabolism Others

Metabolomics Market, By Application:

Biomarker and Drug Discovery Toxicology Nutrigenomics Personalized Medicine Others

Metabolomics Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolomics Market.

Available Customizations:

Global Metabolomics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metabolomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services)
  • 5.2.2. By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, and Others)
  • 5.2.3. By Application (Biomarker and Drug Discovery, Toxicology, Nutrigenomics, Personalized Medicine, and Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map

6. North America Metabolomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Metabolomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Metabolomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Application

7. Europe Metabolomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metabolomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Application
  • 7.3.2. United Kingdom Metabolomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Application
  • 7.3.3. Italy Metabolomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Application
  • 7.3.4. France Metabolomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Metabolomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Application

8. Asia-Pacific Metabolomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metabolomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Application
  • 8.3.2. India Metabolomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Metabolomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Metabolomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Metabolomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Application

9. South America Metabolomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metabolomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Metabolomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Metabolomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Application

10. Middle East and Africa Metabolomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metabolomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Metabolomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Metabolomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Metabolon, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Agilent Technologies, Inc.
• 14.3. Bruker Corporation
• 14.4. Human Metabolome Technologies America, Inc.
• 14.5. Thermo Fisher Scientific Inc.
• 14.6. Shimadzu Corporation
• 14.7. Danaher Corporation
• 14.8. Waters Corporation
• 14.9. Metware Biotechnology Inc.
• 14.10. Afekta Technologies Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer